Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription

Articles published in Acta Radiol

Retrieve available abstracts of 7 articles:
HTML format

Single Articles

    July 2022
  1. STEVENS WM, Parchment-Smith C, Melling PP, Smith JT, et al
    Making an art into a science: a mathematical "Likert tool" can change PI-RADS (v2) scores into Likert scores when reporting multiparametric MRI for prostate cancer.
    Acta Radiol. 2022 Jul 11:2841851221112194. doi: 10.1177/02841851221112194.
    PubMed     Abstract available

    June 2022
  2. MAKELA P, Wright C, Anttinen M, Bostrom PJ, et al
    Safety and efficacy of MRI-guided transurethral ultrasound ablation for radiorecurrent prostate cancer in the presence of gold fiducial markers.
    Acta Radiol. 2022 Jun 24:2841851221108292. doi: 10.1177/02841851221108292.
    PubMed     Abstract available

  3. LEBOVICI A, Csutak C, Popa P, Crisan N, et al
    Magnetic resonance imaging characteristics of chronic prostatitis in patients under the age of 50: is it more than the eye can see?
    Acta Radiol. 2022;63:839-846.
    PubMed     Abstract available

    April 2022
  4. CHUNG JH, Park BK
    Transrectal ultrasound features and biopsy outcomes of transition PI-RADS 5.
    Acta Radiol. 2022;63:559-565.
    PubMed     Abstract available

    February 2022
  5. PARK SB
    Quantitative relaxation maps from synthetic MRI for prostate cancer.
    Acta Radiol. 2022 Feb 24:2841851221077405. doi: 10.1177/02841851221077405.

    September 2021
    International Scientific Prize.
    Acta Radiol. 2021;62:1131.

    June 2021
  7. LINHARES MOREIRA AS, De Visschere P, Van Praet C, Villeirs G, et al
    How does PI-RADS v2.1 impact patient classification? A head-to-head comparison between PI-RADS v2.0 and v2.1.
    Acta Radiol. 2021;62:839-847.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.